CD8A and neoplasm: Next, we explored the induction of tumor-antigen specific immune response in vitro in human with ADD A2L in other words, we investigated the ability of ADDomers to trigger anti-MelA26–35 CD8+ T cells from PBMCs, over 20 days (3 stimulations—one per week) by measuring the percentage of anti-MelA26–35 CD8+ T cells every 7 days using dextramer labeling.